TACC3 and neoplasm: We had previously demonstrated that I-131-labeled ERIC 1 antibodies possess the ability to recognize NCAM-expressing tumor cells in vivo with high efficiency, suggesting their potential as promising agents for the diagnosis and treatment of NCAM-positive neuroblastoma tumors [24].